Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of IBRX is 12 and suggests 89% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell